SPDR S&P Biotech ETF (NYSEARCA:XBI) Reaches New 12-Month High – Should You Buy?

SPDR S&P Biotech ETF (NYSEARCA:XBI)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $139.88 and last traded at $139.59, with a volume of 3270123 shares trading hands. The stock had previously closed at $135.34.

SPDR S&P Biotech ETF Stock Up 4.7%

The company’s fifty day moving average is $132.91 and its two-hundred day moving average is $127.37. The stock has a market cap of $9.04 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85.

Institutional Trading of SPDR S&P Biotech ETF

Hedge funds have recently added to or reduced their stakes in the company. Axiom Investment Management LLC acquired a new stake in SPDR S&P Biotech ETF in the first quarter valued at approximately $26,000. Financial Life Planners acquired a new stake in SPDR S&P Biotech ETF in the first quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $30,000. Finally, SHP Wealth Management acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $31,000.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.